{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:08:29Z","timestamp":1790251709777,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR180044"],"award-info":[{"award-number":["RR180044"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP210868"],"award-info":[{"award-number":["RP210868"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["CA239255, CA2855029, CA285203"],"award-info":[{"award-number":["CA239255, CA2855029, CA285203"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA282099"],"award-info":[{"award-number":["CA282099"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA278787"],"award-info":[{"award-number":["CA278787"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41375-026-03078-y","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:16:28Z","timestamp":1785395788000},"page":"2270-2282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Activating RAR\u03b2 to overcome immunomodulatory drug resistance in t(4;14) human myeloma"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3551-9921","authenticated-orcid":false,"given":"Ling","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6141-0068","authenticated-orcid":false,"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0586-4073","authenticated-orcid":false,"given":"Yufei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youli","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-4129","authenticated-orcid":false,"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-2973","authenticated-orcid":false,"given":"Fenghuang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1529-3398","authenticated-orcid":false,"given":"Qing","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"3078_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Prim. 2024;10:45 .","journal-title":"Nat Rev Dis Prim"},{"key":"3078_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12185-020-03005-6","volume":"113","author":"S Sato","year":"2021","unstructured":"Sato S, Kamata W, Okada S, Tamai Y. Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents. Int J Hematol. 2021;113:207\u201313.","journal-title":"Int J Hematol"},{"key":"3078_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s11912-025-01639-5","volume":"27","author":"B Mohan Lal","year":"2025","unstructured":"Mohan Lal B, van Rhee F, Al Hadidi S. Current state of evidence on definitions and management of high-risk multiple myeloma. Curr Oncol Rep. 2025;27:258\u201377.","journal-title":"Curr Oncol Rep"},{"key":"3078_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13046-024-03217-2","volume":"43","author":"A Giacomini","year":"2024","unstructured":"Giacomini A, Taranto S, Gazzaroli G, Faletti J, Capoferri D, Marcheselli R, et al. The FGF\/FGFR\/c-Myc axis as a promising therapeutic target in multiple myeloma. J Exp Clin Cancer Res. 2024;43:294.","journal-title":"J Exp Clin Cancer Res"},{"key":"3078_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16434-y","volume":"11","author":"SM Foltz","year":"2020","unstructured":"Foltz SM, Gao Q, Yoon CJ, Sun H, Yao L, Li Y, et al. Evolution and structure of clinically relevant gene fusions in multiple myeloma. Nat Commun. 2020;11:2666.","journal-title":"Nat Commun"},{"key":"3078_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.37","volume":"2","author":"A Kalff","year":"2012","unstructured":"Kalff A, Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J. 2012;2:e89.","journal-title":"Blood Cancer J"},{"key":"3078_CR7","doi-asserted-by":"crossref","unstructured":"Wang J, Zhu X, Dang L, Jiang H, Xie Y, Li X, et al. Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation. J Clin Invest 2022;132:e149526.","DOI":"10.1172\/JCI149526"},{"key":"3078_CR8","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1182\/blood-2005-10-4179","volume":"107","author":"S Trudel","year":"2006","unstructured":"Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S, et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood. 2006;107:4039\u201346.","journal-title":"Blood"},{"key":"3078_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1158\/1078-0432.CCR-08-1612","volume":"15","author":"G Bisping","year":"2009","unstructured":"Bisping G, Wenning D, Kropff M, Gustavus D, M\u00fcller-Tidow C, Stelljes M, et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. Clin Cancer Res. 2009;15:520\u201331.","journal-title":"Clin Cancer Res"},{"key":"3078_CR10","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1182\/blood.2022018007","volume":"141","author":"B Paiva","year":"2023","unstructured":"Paiva B, Calasanz MJ. Highs and lows of t(4;14) in multiple myeloma. Blood. 2023;141:1500\u20132.","journal-title":"Blood"},{"key":"3078_CR11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2023-174177","volume":"142","author":"S Bird","year":"2023","unstructured":"Bird S, Pawlyn C. IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact. Blood. 2023;142:131\u201340.","journal-title":"Blood"},{"key":"3078_CR12","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3324\/haematol.2024.285636","volume":"110","author":"PJ Teoh","year":"2025","unstructured":"Teoh PJ, Koh MY, Mitsiades C, Gooding S, Chng WJ. Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. Haematologica. 2025;110:1074\u201391.","journal-title":"Haematologica"},{"key":"3078_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.4306","volume":"23","author":"SM Corsello","year":"2017","unstructured":"Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat Med. 2017;23:405\u20138.","journal-title":"Nat Med"},{"key":"3078_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/blood.V72.2.567.567","volume":"72","author":"ME Huang","year":"1988","unstructured":"Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567\u201372.","journal-title":"Blood"},{"key":"3078_CR15","first-page":"2154","volume":"10","author":"SJ Collins","year":"1990","unstructured":"Collins SJ, Robertson KA, Mueller L. Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). Mol Cell Biol. 1990;10:2154\u201363.","journal-title":"Mol Cell Biol"},{"key":"3078_CR16","first-page":"3743","volume":"12","author":"KA Robertson","year":"1992","unstructured":"Robertson KA, Emami B, Mueller L, Collins SJ. Multiple members of the retinoic acid receptor family are capable of mediating the granulocytic differentiation of HL-60 cells. Mol Cell Biol. 1992;12:3743\u20139.","journal-title":"Mol Cell Biol"},{"key":"3078_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0173-0","volume":"9","author":"YX Zhu","year":"2019","unstructured":"Zhu YX, Shi C-X, Bruins LA, Wang X, Riggs DL, Porter B, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 2019;9:19.","journal-title":"Blood Cancer J"},{"key":"3078_CR18","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326\u201335.","journal-title":"Leukemia"},{"key":"3078_CR19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"3078_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/sj.cdd.4400673","volume":"7","author":"M Gianni","year":"2000","unstructured":"Gianni M, Ponzanelli I, Mologni L, Reichert U, Rambaldi A, Terao M, et al. Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases. Cell Death Differ. 2000;7:447\u201360.","journal-title":"Cell Death Differ"},{"key":"3078_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrm3932","volume":"16","author":"TJ Cunningham","year":"2015","unstructured":"Cunningham TJ, Duester G. Mechanisms of retinoic acid signalling and its roles in organ and limb development. Nat Rev Mol Cell Biol. 2015;16:110\u201323.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3078_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01399-w","volume":"9","author":"R He","year":"2023","unstructured":"He R, Liu B, Geng B, Li N, Geng Q. The role of HDAC3 and its inhibitors in regulation of oxidative stress and chronic diseases. Cell Death Discov. 2023;9:131.","journal-title":"Cell Death Discov"},{"key":"3078_CR23","doi-asserted-by":"publisher","first-page":"M110.004317","DOI":"10.1074\/mcp.M110.004317","volume":"10","author":"TM Greco","year":"2011","unstructured":"Greco TM, Yu F, Guise AJ, Cristea IM. Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation. Mol Cell Proteom. 2011;10:M110.004317.","journal-title":"Mol Cell Proteom"},{"key":"3078_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.661620","volume":"11","author":"J Yang","year":"2021","unstructured":"Yang J, Gong C, Ke Q, Fang Z, Chen X, Ye M, et al. Insights into the function and clinical application of HDAC5 in cancer management. Front Oncol. 2021;11:661620.","journal-title":"Front Oncol"},{"key":"3078_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.pharmthera.2014.02.012","volume":"143","author":"GH Eom","year":"2014","unstructured":"Eom GH, Kook H. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases. Pharm Ther. 2014;143:168\u201380.","journal-title":"Pharm Ther"},{"key":"3078_CR26","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"3078_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00359-2","volume":"10","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94.","journal-title":"Blood Cancer J"},{"key":"3078_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1158\/2643-3230.BCD-21-0205","volume":"3","author":"FE Davies","year":"2022","unstructured":"Davies FE, Pawlyn C, Usmani SZ, San-Miguel JF, Einsele H, Boyle EM, et al. Perspectives on the risk-stratified treatment of multiple myeloma. Blood Cancer Discov. 2022;3:273\u201384.","journal-title":"Blood Cancer Discov"},{"key":"3078_CR29","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","volume":"124","author":"MA Krook","year":"2021","unstructured":"Krook MA, Reeser JW, Ernst G, Barker H, Wilberding M, Li G, et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer. 2021;124:880\u201392.","journal-title":"Br J Cancer"},{"key":"3078_CR30","doi-asserted-by":"crossref","unstructured":"Katoh M FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med 2016;38:3\u201315.","DOI":"10.3892\/ijmm.2016.2620"},{"key":"3078_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305\u20139.","journal-title":"Science"},{"key":"3078_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301\u20135.","journal-title":"Science"},{"key":"3078_CR33","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1182\/blood.2022015909","volume":"140","author":"S Gooding","year":"2022","unstructured":"Gooding S, Ansari-Pour N, Kazeroun M, Karagoz K, Polonskaia A, Salazar M, et al. Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma. Blood. 2022;140:1816\u201321.","journal-title":"Blood"},{"key":"3078_CR34","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2018-01-821769","volume":"132","author":"QL Sievers","year":"2018","unstructured":"Sievers QL, Gasser JA, Cowley GS, Fischer ES, Ebert BL. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood. 2018;132:1293\u2013303.","journal-title":"Blood"},{"key":"3078_CR35","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nm.4128","volume":"22","author":"R Eichner","year":"2016","unstructured":"Eichner R, Heider M, Fern\u00e1ndez-S\u00e1iz V, van Bebber F, Garz A-K, Lemeer S, et al. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med. 2016;22:735\u201343.","journal-title":"Nat Med"},{"key":"3078_CR36","doi-asserted-by":"crossref","unstructured":"Heider M, Eichner R, Stroh J, Morath V, Kuisl A, Zecha J, et al. The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. Mol Cell 2021;81:1170\u201386.e10.","DOI":"10.1016\/j.molcel.2020.12.046"},{"key":"3078_CR37","doi-asserted-by":"crossref","unstructured":"Liu J, Hideshima T, Xing L, Wang S, Zhou W, Samur MK, et al. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021;7:eabg2697.","DOI":"10.1126\/sciadv.abg2697"},{"key":"3078_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28515-1","volume":"13","author":"YLD Ng","year":"2022","unstructured":"Ng YLD, Ramberger E, Bohl SR, Dolnik A, Steinebach C, Conrad T, et al. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nat Commun. 2022;13:1009.","journal-title":"Nat Commun"},{"key":"3078_CR39","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/leu.2014.238","volume":"29","author":"EM Ocio","year":"2015","unstructured":"Ocio EM, Fern\u00e1ndez-L\u00e1zaro D, San-Segundo L, L\u00f3pez-Corral L, Corchete LA, Guti\u00e9rrez NC, et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia. 2015;29:705\u201314.","journal-title":"Leukemia"},{"key":"3078_CR40","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1182\/blood.2020007081","volume":"137","author":"S Gooding","year":"2021","unstructured":"Gooding S, Ansari-Pour N, Towfic F, Ortiz Est\u00e9vez M, Chamberlain PP, Tsai K-T, et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 2021;137:232\u20137.","journal-title":"Blood"},{"key":"3078_CR41","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659\u201361.","journal-title":"FASEB J"},{"key":"3078_CR42","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/leu.2014.60","volume":"28","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28:1573\u201385.","journal-title":"Leukemia"},{"key":"3078_CR43","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/ciia.2006.1.4.327","volume":"1","author":"S Mukherjee","year":"2006","unstructured":"Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Inter Aging. 2006;1:327\u201348.","journal-title":"Clin Inter Aging"},{"key":"3078_CR44","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1310\/hpj5108-628","volume":"51","author":"E Damery","year":"2016","unstructured":"Damery E, Solimando DA Jr., Waddell JA. Arsenic trioxide and tretinoin (AsO\/ATRA) for acute promyelocytic leukemia (APL). Hosp Pharm. 2016;51:628\u201332.","journal-title":"Hosp Pharm"},{"key":"3078_CR45","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJM198510033131401","volume":"313","author":"EJ Lammer","year":"1985","unstructured":"Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313:837\u201341.","journal-title":"N Engl J Med"},{"key":"3078_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/cosmetics12010017","volume":"12","author":"W Tawanwongsri","year":"2025","unstructured":"Tawanwongsri W, Kanchanasuwan T, Eden C. Isotretinoin and hepatotoxicity in patients with acne: a narrative review. Cosmetics. 2025;12:17.","journal-title":"Cosmetics"},{"key":"3078_CR47","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.2147\/IJN.S142503","volume":"12","author":"T Subongkot","year":"2017","unstructured":"Subongkot T, Ngawhirunpat T. Development of a novel microemulsion for oral absorption enhancement of all-trans retinoic acid. Int J Nanomed. 2017;12:5585\u201399.","journal-title":"Int J Nanomed"},{"key":"3078_CR48","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/j.1552-4604.1983.tb01800.x","volume":"23","author":"WA Colburn","year":"1983","unstructured":"Colburn WA, Gibson DM, Wiens RE, Hanigan JJ. Food increases the bioavailability of isotretinoin. J Clin Pharm. 1983;23:534\u20139.","journal-title":"J Clin Pharm"},{"key":"3078_CR49","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood.2020009856","volume":"139","author":"Q Wang","year":"2022","unstructured":"Wang Q, Lin Z, Wang Z, Ye L, Xian M, Xiao L, et al. RAR\u03b3 activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood. 2022;139:59\u201372.","journal-title":"Blood"},{"key":"3078_CR50","doi-asserted-by":"publisher","first-page":"10799","DOI":"10.1074\/jbc.M111.321836","volume":"287","author":"JH Shi","year":"2012","unstructured":"Shi JH, Zheng B, Chen S, Ma GY, Wen JK. Retinoic acid receptor \u03b1 mediates all-trans-retinoic acid-induced Klf4 gene expression by regulating Klf4 promoter activity in vascular smooth muscle cells. J Biol Chem. 2012;287:10799\u2013811.","journal-title":"J Biol Chem"},{"key":"3078_CR51","doi-asserted-by":"crossref","unstructured":"Ghyselinck NB, Duester G. Retinoic acid signaling pathways. Development. 2019;146:dev167502.","DOI":"10.1242\/dev.167502"},{"key":"3078_CR52","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1242\/dev.112367","volume":"141","author":"S Kumar","year":"2014","unstructured":"Kumar S, Duester G. Retinoic acid controls body axis extension by directly repressing Fgf8 transcription. Development. 2014;141:2972\u20137.","journal-title":"Development"},{"key":"3078_CR53","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1126\/science.7916164","volume":"265","author":"M Studer","year":"1994","unstructured":"Studer M, P\u00f6pperl H, Marshall H, Kuroiwa A, Krumlauf R. Role of a conserved retinoic acid response element in rhombomere restriction of Hoxb-1. Science. 1994;265:1728\u201332.","journal-title":"Science"},{"key":"3078_CR54","doi-asserted-by":"crossref","unstructured":"Xiong S, Zhou J, Chng WJ. Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails. Blood. 2025;146:1550\u201360.","DOI":"10.1182\/blood.2025028403"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03078-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03078-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03078-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:43:35Z","timestamp":1790250215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03078-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3078"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03078-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Murine experiments were performed in accordance with the protocol (#IS00008301) approved by the Institutional Animal Care and Use Committee of the Houston Methodist Research Institute. MM patient samples were obtained from an IRB-approved tissue bank (#Pro00019970) at the Houston Methodist Research Institute. All patients provided written informed consent.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}